GMAB vs. ONC: Genmab vs. BeOne Medicines Stock Comparison
How do Genmab (GMAB) and BeOne Medicines (ONC) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Genmab (GMAB) and BeOne Medicines (ONC) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
Both Genmab (GMAB) and BeOne Medicines (ONC) trade as ADRs — their core financials are comparable, but keep FX, depositary-program fees, and dividend withholding in view for each.
| Profile Item | GMAB | ONC |
|---|---|---|
| Name | Genmab A/S American Depositary Shares | BeOne Medicines Ltd. American Depositary Shares |
| Country/Region | Denmark | Switzerland |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 32.98 billion USD | 46.49 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | June 1, 2009 | February 3, 2016 |
| Security Type | ADR | ADR |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | GMAB | ONC |
|---|---|---|
| Total Return (1Y) | 91.17% | 30.59% |
| Total Return (3Y, Annualized) | 20.70% | 30.15% |
| Total Return (5Y, Annualized) | 3.98% | 2.48% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | GMAB | ONC |
|---|---|---|
| Volatility (1Y, Annualized) | 45.68% | 35.90% |
| Beta (5Y) | 0.72 | 0.59 |
| Max Drawdown (5Y) | -61.79% | -68.89% |
| Avg. Volume (3M) | 4.09M | 405.29K |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | GMAB | ONC |
|---|---|---|
| Sharpe Ratio (1Y) | 1.90 | 0.73 |
| Sortino Ratio (1Y) | 3.82 | 1.15 |
Profitability
ROE (TTM)
Both Genmab (GMAB) at 12.07% and BeOne Medicines (ONC) at 18.40% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
12.07%
- Max
- 109.18%
- GMAB
- 12.07%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
18.40%
- Max
- 109.18%
- ONC
- 18.40%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
For every dollar of sales, both Genmab (GMAB) at 16.97% and BeOne Medicines (ONC) at 13.86% retain more as net profit than most peers, landing in the top net margin quartile of their industries.
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
16.97%
- Max
- 18.05%
- GMAB
- 16.97%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
13.86%
- Max
- 18.05%
- ONC
- 13.86%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Genmab (GMAB) at 37.15% and BeOne Medicines (ONC) at 22.15% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
37.15%
- Max
- 83.12%
- GMAB
- 37.15%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
22.15%
- Max
- 83.12%
- ONC
- 22.15%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | GMAB | ONC |
|---|---|---|
| ROE (TTM) | 12.07% | 18.40% |
| ROA (TTM) | 8.24% | 8.42% |
| Net Margin (TTM) | 16.97% | 13.86% |
| Operating Margin (TTM) | 37.15% | 22.15% |
| Gross Margin (TTM) | 92.67% | 89.39% |
Growth
Revenue Growth
Both Genmab (GMAB) at 19.19% and BeOne Medicines (ONC) at 40.23% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Only one side can be read here: Genmab (GMAB) reports EPS growth of -9.23%, ranked against its industry; BeOne Medicines (ONC) has no EPS growth figure this period.
Growth Metrics
| Metric | GMAB | ONC |
|---|---|---|
| Revenue Growth (YoY) | 19.19% | 40.23% |
| Revenue Growth (3Y CAGR) | 21.23% | 55.69% |
| EPS Growth (YoY) | -9.23% | -- |
| EPS Growth (3Y CAGR) | 8.48% | -- |
Financial Strength
Current Ratio (MRQ)
BeOne Medicines (ONC) at 3.55 keeps current ratio within its industry’s typical mid-range, while Genmab (GMAB) at 2.45 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for GMAB.
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.45
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- GMAB
- 2.45
- Min
- 0.10
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.55
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- ONC
- 3.55
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
BeOne Medicines (ONC) at 0.35 carries an industry-typical debt-to-equity mix, while Genmab (GMAB) at 0.82 uses more debt funding than most peers.
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.82
- Max
- 1.42
- GMAB
- 0.82
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.35
- Max
- 1.42
- Q3
- 0.65
- ONC
- 0.35
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | GMAB | ONC |
|---|---|---|
| Current Ratio (MRQ) | 2.45 | 3.55 |
| Debt / Equity (MRQ) | 0.82 | 0.35 |
| Net Debt / EBITDA | 2.45 | -2.80 |
Dividends
Dividend Yield (TTM)
Neither Genmab (GMAB) nor BeOne Medicines (ONC) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- GMAB
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ONC
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Genmab (GMAB) nor BeOne Medicines (ONC) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- GMAB
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ONC
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | GMAB | ONC |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
Both Genmab (GMAB) at 45.84 and BeOne Medicines (ONC) at 52.17 sit in the richer earnings-multiple quartile for P/E ratio, so investors are paying more for TTM earnings than they pay for typical peers.
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
45.84
- Max
- 85.34
- GMAB
- 45.84
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
52.17
- Max
- 85.34
- ONC
- 52.17
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Genmab (GMAB) at 7.68 and BeOne Medicines (ONC) at 7.04 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.68
- Max
- 58.18
- Q3
- 25.77
- GMAB
- 7.68
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.04
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- ONC
- 7.04
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Genmab (GMAB) at 5.36 is valued about in line with its industry on P/B ratio, while BeOne Medicines (ONC) at 7.98 carries an above-peer premium to book — ONC is pricier on assets.
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.36
- Max
- 13.53
- Q3
- 6.54
- GMAB
- 5.36
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.98
- Max
- 13.53
- ONC
- 7.98
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | GMAB | ONC |
|---|---|---|
| P/E Ratio (TTM) | 45.84 | 52.17 |
| P/S Ratio (TTM) | 7.68 | 7.04 |
| P/B Ratio (MRQ) | 5.36 | 7.98 |
| Free Cash Flow Yield (TTM) | 2.59% | 2.21% |